Core Insights - Guangzhou Pharmaceutical Group Co., Ltd. (referred to as "Guangyao Group") has established a joint venture named Guangzhou Baiyunshan (600332) Xihe Health Pharmaceutical Co., Ltd. (referred to as "Baiyunshan Xihe Health") with the Xiamen Rare Earth Research Institute to enter the nuclear medicine sector [1][2] - Nuclear medicine, which involves radioactive drugs for diagnosis and treatment, is becoming a strategic focus for the global biopharmaceutical industry, with major pharmaceutical companies investing in this area [1] - The Chinese government has introduced policies to support the development of the nuclear medicine industry, including the "Medical Isotope Medium and Long-term Development Plan (2021-2035)" [1] Company Developments - Baiyunshan Xihe Health was established on August 15 with a registered capital of 50 million yuan, co-funded by Guangyao Group and the Xiamen Rare Earth Research Institute [2] - The technical team of Baiyunshan Xihe Health successfully produced high-quality Zirconium-89 using an advanced domestic solid target system, filling a gap in domestic production [2] - Guangyao Group has set clear goals: short-term focus on rapid industrialization of rare earth diagnostic and therapeutic nuclear products; mid-term plans to build a nuclear production and R&D base; and long-term commitment to providing smart nuclear medical solutions [2]